Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RT302
- Development stage
- Preclinical
- Lead developer
- Revio Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
RT302 is a drug candidate under development by Revio Therapeutics as part of its reformulation pipeline. The program focuses on the optimization of a proven therapeutic agent into an oral solution formulation specifically for applications in haematology. By utilizing an oral solution delivery method, the program aims to enhance the pharmacokinetic profile, ease of administration, or patient compliance compared to existing versions of the drug. As of the current pipeline status, RT302 is in the preclinical development stage, specifically progressing through CMC (Chemistry, Manufacturing, and Controls) development and bridging studies.
Beyond the preview
Go deeper on RT302.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RT302.